PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-21.01%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Operating expenses reduction while Biotechnology median is 3.58%. Seth Klarman would investigate advantages.
-10.76%
Total costs reduction while Biotechnology median is 3.71%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth exceeding 1.5x Biotechnology median of 0.19%. Jim Chanos would check for overinvestment.
10.97%
EBITDA change of 10.97% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Other expenses change of 104.37% versus flat Biotechnology. Walter Schloss would verify control.
11.35%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense change of 305.13% versus flat Biotechnology. Walter Schloss would verify strategy.
11.35%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS change of 31.03% versus flat Biotechnology. Walter Schloss would verify quality.
31.72%
Diluted EPS change of 31.72% versus flat Biotechnology. Walter Schloss would verify quality.
29.31%
Share count reduction below 50% of Biotechnology median of 0.03%. Jim Chanos would check for issues.
29.44%
Diluted share reduction below 50% of Biotechnology median of 0.01%. Jim Chanos would check for issues.